Please Wait.....
Report
T Cell Lymphoma Pipeline Insight Analysis Report
Market Report I 2024-08-29 I 150 Pages I EMR Inc.
T Cell Lymphoma Drug Pipeline Analysis 2024
T cell lymphoma is a type of non-Hodgkin lymphoma that originates in T cells, a vital component of the immune system. This cancer is characterized by the rapid growth and proliferation of malignant T cells, leading to various symptoms, including swollen lymph nodes, skin rashes, and systemic involvement. It accounts for about 10-15% of all non-Hodgkin lymphomas, with a higher prevalence in older adults.
Key Takeaways
- Key players in the T cell lymphoma drug pipeline market include Legend Biotech USA Inc., Eisai Inc., Takeda, Corvus Pharmaceuticals, Inc., Rhizen Pharmaceuticals SA, and Antengene Corporation. These companies are at the forefront of developing cutting-edge therapies to improve patient outcomes.
- The drug pipeline for T cell lymphoma includes promising candidates such as Lenalidomide, BMS-986369, and Isatuximab SAR650984. These treatments focus on modulating the immune response, targeting specific cancer cell markers, and providing innovative approaches to control the disease and enhance survival rates.
- Regulatory agencies are encouraging the development of novel T cell lymphoma treatments by providing incentives such as fast-track designations and priority reviews. This support is crucial for facilitating quicker access to new and effective therapies for patients, addressing the urgent need for better treatment options in this challenging condition.
Report Coverage
The T cell lymphoma treatment pipeline analysis provides an overview of recent advancements and ongoing clinical trials. The report highlights progress in developing novel therapies, including immune-modulating drugs, monoclonal antibodies, and targeted therapies, aiming for effective disease control and long-term management. It covers innovative approaches such as personalized medicine, which tailors treatments based on individual patient profiles, and advanced diagnostic technologies for improved treatment efficacy.
T Cell Lymphoma Drug Pipeline Outlook
T-cell lymphoma is a rare and aggressive form of non-Hodgkin lymphoma originating from T-lymphocytes, which are a type of white blood cell vital for immune function. This cancer includes various subtypes, such as Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma, each presenting unique clinical challenges. Symptoms often include enlarged lymph nodes, skin rashes, and systemic involvement. T-cell lymphomas typically require complex treatment strategies due to their heterogeneous nature and resistance to conventional therapies.
Recent advancements focus on targeted therapies and personalized medicine to improve patient outcomes by addressing the specific molecular and genetic characteristics of the disease.
In 2024, significant advancements in T-cell lymphoma treatment have been made. The FDA approved lisocabtagene maraleucel (Breyanzi) as a CAR T-cell therapy for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), offering new treatment options for patients with T-cell lymphomas that have not responded to other therapies. This approval highlights the continued innovation and development of CAR T-cell therapies in treating lymphomas.
These approvals and ongoing developments underscore the dynamic and evolving nature of T-cell lymphoma therapeutics, providing new treatment options and hope for improved patient outcomes.
T Cell Lymphoma- Pipeline Drug Profiles
Recent developments in the treatment of T cell lymphoma have introduced several promising drugs currently in clinical trials, reflecting significant advancements in the field.
- Lenalidomide: Lenalidomide is an immunomodulatory drug that enhances the immune system's ability to fight cancer cells by modulating cytokine production and inhibiting angiogenesis. It is being evaluated for its efficacy in combination with other therapies to improve outcomes in patients with T-cell lymphoma.
- BMS-986369: BMS-986369 is an investigational drug developed by Bristol-Myers Squibb. It targets specific signaling pathways involved in T cell proliferation and survival, aiming to control tumor growth and enhance patient response to treatment.
- Isatuximab SAR650984: Isatuximab is a monoclonal antibody targeting CD38, a protein expressed on the surface of T cell lymphoma cells. It works by inducing immune-mediated cell death and is being studied in combination with other agents to improve its therapeutic efficacy.
Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of T cell lymphoma drug based on various segmentations such as:
Analysis by Route of Administration
- Oral
Oral medications for T-cell lymphoma offer a convenient option for long-term management, allowing patients to take treatments at home. This route is exemplified by drugs like lenalidomide, which are administered orally to maintain consistent therapeutic levels and improve adherence to the treatment regimen. The convenience of oral administration supports patient autonomy and helps integrate treatment into daily life, reducing the need for frequent hospital visits.
- Parenteral
Parenteral administration, such as intravenous (IV) infusions, is used for delivering potent therapeutic agents directly into the bloodstream. This method is crucial for aggressive T-cell lymphomas, providing rapid and effective drug delivery to achieve optimal therapeutic levels quickly. Treatments like monoclonal antibodies and chemotherapy agents are often administered this way to ensure immediate action against malignant cells and to manage severe disease forms.
- Others
Other routes of administration, such as subcutaneous injections and targeted delivery systems, are being developed to enhance patient comfort and therapeutic outcomes. These methods aim to improve the delivery and efficacy of treatments while minimizing side effects, offering alternative options for patients who may have difficulty with traditional administration routes.
Analysis by Phase
According to EMR analysis, Phase II clinical trials dominate the T cell lymphoma drug pipeline. The number of T cell lymphoma drugs currently in Phase 2 clinical trials varies as new trials are continually initiated and completed. However, as of the latest data, there are over 1,000 ongoing Phase 3 trials for T cell lymphoma drugs worldwide. These trials involve a wide range of therapeutic approaches, including targeted therapies, immunotherapies, and combination treatments.
- Preclinical Phase: Laboratory and animal studies to assess safety and efficacy.
- Phase I: Small-scale human trials focusing on safety and dosage.
- Phase II: Larger trials to evaluate efficacy and side effects.
- Phase III: Large-scale trials to confirm effectiveness, monitor side effects, and compare with standard treatments.
- Phase IV: Post-marketing studies to gather more information on risks, benefits, and optimal use.
Analysis by Drug Class
- Oligonucleotide
Oligonucleotide drugs are short DNA or RNA sequences designed to specifically bind to and modify genetic material within cancer cells, targeting specific oncogenic pathways. By disrupting these pathways, they offer a precision medicine approach to T-cell lymphoma treatment. This class of drugs can interfere with the expression of genes critical to cancer cell survival and proliferation, potentially halting disease progression and offering a tailored therapeutic strategy.
- Peptide
Peptide-based therapies utilize short chains of amino acids that interact with biological targets to modulate cellular functions. These therapies offer novel mechanisms for combating T-cell lymphoma by targeting and inhibiting specific proteins or signaling pathways involved in cancer cell growth. Peptides can be designed to interfere with cell signaling or induce an immune response against cancer cells, providing a unique approach to treatment.
- Small Molecule
Small molecule drugs are characterized by their low molecular weight, which enables them to penetrate cell membranes easily and interact with intracellular targets. In T-cell lymphoma therapy, these molecules inhibit key oncogenic pathways by blocking the activity of proteins essential for cancer cell survival and proliferation. They are particularly effective in treating resistant forms of T-cell lymphoma and can be used in combination with other therapies to enhance treatment efficacy.
T Cell Lymphoma Drug Clinical Trials Assessment- Competitive Dynamics
Here are a few notable participants involved in T cell lymphoma research and development:
These advancements represent significant steps forward in T cell lymphoma treatment, potentially offering patients more effective and less burdensome options.
Celgene: Based in Summit, New Jersey, Celgene is a leader in hematology, focusing on innovative therapies for T-cell lymphoma. The company leverages its expertise in immunomodulation and targeted treatments, such as lenalidomide, to enhance patient outcomes. Celgene is dedicated to advancing research and development in oncology, aiming to improve therapeutic options and quality of life for patients with hematologic cancers.
Hebei Senlang Biotechnology Inc., Ltd.: This company, located in Shijiazhuang, China, specializes in cellular immunotherapy and is pioneering the development of CAR-T cell therapies for T-cell lymphoma. By engineering patients' T-cells to target cancer cells, Hebei Senlang Biotechnology provides personalized and effective treatment options, aiming to revolutionize the management of this aggressive cancer.
Bristol-Myers Squibb: Headquartered in New York City, Bristol-Myers Squibb is renowned for its robust oncology portfolio, including a strong focus on T-cell lymphoma. The company is committed to advancing treatment through novel targeted therapies and immune-based treatments, such as checkpoint inhibitors, to enhance the body's ability to fight cancer. Bristol-Myers Squibb's research is dedicated to developing innovative solutions that improve patient outcomes and extend survival.
CRISPR Therapeutics AG: Located in Basel, Switzerland, CRISPR Therapeutics is at the forefront of gene-editing technology, exploring innovative approaches to treat T-cell lymphoma. By correcting genetic mutations and enhancing immune system responses, the company aims to develop transformative therapies that target the root causes of cancer. CRISPR Therapeutics' research focuses on leveraging its cutting-edge CRISPR-Cas9 platform to deliver precise and effective cancer treatments.
Other key players in the market include Legend Biotech USA Inc., Eisai Inc., Takeda, Corvus Pharmaceuticals, Inc., Rhizen Pharmaceuticals SA, Antengene Corporation, Rigel Pharmaceuticals, iCell Gene Therapeutics, Dizal Pharmaceuticals, SciTech Development, LLC, Jiangsu HengRui Medicine Co., Ltd., Sanofi.
Reasons To Purchase This Report
The T cell lymphoma drug pipeline analysis report offers invaluable insights into the latest advancements and future trends in T cell lymphoma treatment. It provides detailed evaluations of emerging therapies, pipeline assessment, and competitive landscape analysis, enabling informed investment decisions and strategic planning.
Key Questions Answered in the T Cell Lymphoma Drug Pipeline Analysis Report
- What is the current state of the T cell lymphoma drug pipeline?
- How many companies are currently involved in T cell lymphoma drug development?
- What is the number of drugs in Phase III and Phase IV trials for T-cell lymphoma?
- Which organisations are at the forefront of T cell lymphoma drug research?
- What are the effectiveness and safety profiles of the drugs in the T cell lymphoma pipeline?
- What opportunities and challenges exist in the T cell lymphoma clinical trial landscape?
- Which companies are leading the major clinical trials for T cell lymphoma drugs?
- Which regions are involved in clinical trials for T-cell lymphoma?
- What are the recent clinical trial results for T cell lymphoma drugs?
- What are the emerging trends in T cell lymphoma clinical trials?
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Overview of T Cell Lymphoma
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 T Cell Lymphoma: Epidemiology Snapshot
5.1 T Cell Lymphoma Incidence by Key Markets
5.2 T Cell Lymphoma- Patients Seeking Treatment in Key Markets
6 T Cell Lymphoma: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 T Cell Lymphoma: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 T Cell Lymphoma, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of T Cell Lymphoma Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 T Cell Lymphoma Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Brentuximab vedotin
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Azacitidine
10.2.3 Pralatrexate
10.2.4 Other Drug
11 T Cell Lymphoma Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 LIS1
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Alemtuzumab (Campath-1H)
11.2.3 Other Drugs
12 T Cell Lymphoma Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 LB1901
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 CPI-818
12.2.3 Tenalisib
12.2.4 Other Drugs
13 T Cell Lymphoma Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 PEG-L-Asparaginase
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 CTA30X UCAR-T
13.2.3 Other Drugs
14 T Cell Lymphoma, Key Drug Pipeline Companies
14.1 Celgene
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Hebei Senlang Biotechnology Inc., Ltd.
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Bristol-Myers Squibb
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 CRISPR Therapeutics AG
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Legend Biotech USA Inc.
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Eisai Inc.
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Takeda
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
14.8 Corvus Pharmaceuticals, Inc.
14.8.1 Company Snapshot
14.8.2 Pipeline Product Portfolio
14.8.3 Financial Analysis
14.8.4 Recent News and Developments
14.9 Rhizen Pharmaceuticals SA
14.9.1 Company Snapshot
14.9.2 Pipeline Product Portfolio
14.9.3 Financial Analysis
14.9.4 Recent News and Developments
14.10 Antengene Corporation
14.10.1 Company Snapshot
14.10.2 Pipeline Product Portfolio
14.10.3 Financial Analysis
14.10.4 Recent News and Developments
14.11 Rigel Pharmaceuticals
14.11.1 Company Snapshot
14.11.2 Pipeline Product Portfolio
14.11.3 Financial Analysis
14.11.4 Recent News and Developments
14.12 iCell Gene Therapeutics
14.12.1 Company Snapshot
14.12.2 Pipeline Product Portfolio
14.12.3 Financial Analysis
14.12.4 Recent News and Developments
14.13 Dizal Pharmaceuticals
14.13.1 Company Snapshot
14.13.2 Pipeline Product Portfolio
14.13.3 Financial Analysis
14.13.4 Recent News and Developments
14.14 SciTech Development, LLC
14.14.1 Company Snapshot
14.14.2 Pipeline Product Portfolio
14.14.3 Financial Analysis
14.14.4 Recent News and Developments
14.15 Jiangsu HengRui Medicine Co., Ltd.
14.15.1 Company Snapshot
14.15.2 Pipeline Product Portfolio
14.15.3 Financial Analysis
14.15.4 Recent News and Developments
14.16 Sanofi
14.16.1 Company Snapshot
14.16.2 Pipeline Product Portfolio
14.16.3 Financial Analysis
14.16.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products
*Complete list of drugs covered will be provided in the report.
The EMR team aims to provide comprehensive coverage of the Top Drugs for each Phase, considering factors such as the company's financial standing, geographic presence, and market position to ensure thorough analysis in this section.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security